Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GM mosquito trial will...

    GM mosquito trial will not significantly impact environment: FDA

    Written by savita thakur thakur Published On 2016-08-08T12:38:54+05:30  |  Updated On 8 Aug 2016 12:38 PM IST
    GM mosquito trial will not significantly impact environment: FDA

    The U.S. Food and Drug Administration said that a field trial testing Intrexon Corp's genetically engineered mosquitoes, meant to be used in the battle against Zika, would not have a significant impact on the environment.


    The company wants to conduct a trial in the Florida Keys to assess the effectiveness of the genetically modified mosquitoes in reducing populations of Aedes mosquitoes, which can spread diseases including Zika, dengue, yellow fever and chikungunya.


    Florida began aerial spraying on Thursday to kill mosquitoes in a Miami neighborhood with the first U.S. spread of the Zika virus. Health authorities have identified 15 Zika cases spread by local mosquitoes and expect there may be more.


    The mosquitoes are genetically altered so their offspring die before they can reproduce.


    Trials in Brazil, Panama and the Cayman Islands showed that Intrexon's mosquitoes can reduce localized Aedes aegypti populations by more than 90 percent.


    The current Zika outbreak was first detected last year in Brazil, where it has been linked to more than 1,700 cases of microcephaly, a birth defect marked by small head size that can lead to severe developmental problems in babies.


    The virus has spread rapidly through the Americas and Caribbean and its arrival in the continental United States, where Aedes aegypti mosquitoes thrive in the warmer southern states, had been widely anticipated.


    The GM mosquito strain is made by Oxitec, a spin-off company from Oxford University that is now a UK subsidiary of U.S. based Intrexon.

    chikungunyaDengueIntrexon Corp'sMosquitoOxford UniversityUS Food & Drug AdministrationUSFDAyellow feverZikazika virus
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok